Creating a healthcare system that prioritizes a well-informed consumer and rewards improvements in quality requires overhauling the current system. Through a series of programs and initiatives, CMS, under Administrator Seema Verma’s leadership, is trying to fix some of the issues that plague the current US health system and make accessing care challenging for patients.
The addition of daratumumab to standard treatment of lenalidomide and dexamethasone for patients with multiple myeloma, who were ineligible for autologous stem-cell transplant, was found to significantly lower the risk of disease progression or death compared with those who only received standard treatment.
https://www.pharmacytimes.org/on-demand/managing-vasoocclusive-crisis-in-sickle-cell-disease-a-look-at-the-clinical-and-economic-burden
Lack of awareness of hypoglycemia symptoms can be dangerous, because the person with diabetes can experience a dangerous drop in blood sugar; chronic low blood glucose can result in complications.
https://www.pharmacytimes.org/on-demand/ajmc-payer-and-specialty-pharmacy-forum-improving-the-adoption-of-oncology-biosimilars-in-practice
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Here are the top 5 articles for the month of May.
There have been 91 cases of measles in the last week and a half, bringing the number of cases so far this year to 971; a coalition of civil rights group is suing the Trump administration over the recently issued conscience protection rule; Oklahoma's opioid trial against Johnson & Johnson has started.
This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.
According to results from a recent retrospective study, patients previously diagnosed with a hematologic malignancy were found to be at a higher risk of developing head and neck cancers compared with patients without a prior hematologic malignancy.
While women reported smoking less than men, they were found to be more severely affected by chronic obstructive pulmonary disease.
The American Heart Association has called for the creation of specialized, multidisciplinary, clinical programs that combine focused expertise in the fields of genetics and cardiovascular medicine.
https://www.pharmacytimes.org/on-demand/ajmc-payer-forum-reducing-influenza-duration-related-complications-and-healthcare-costs-with-novel-antivirals
Testing for minimal residual disease (MRD) is increasingly being used in patients with cancer because deep MRD negativity is associated with better outcomes for patients and MRD status can help make decisions regarding treatment. Two abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting validated use of MRD testing in the real world and found it was cost-effective.
Children allergic to peanuts have higher total healthcare costs and consume more healthcare services, including emergency department (ED) visits, and had comorbidities of allergic rhinitis, asthma, and atopic dermatitis, than those without the allergy.
Patients who switched from ozanimod HCI 0.5 mg or interferon β-1a to ozanimod HCI 1.0 mg in an open-label extension study experienced sustained reduction in their annualized relapse rate. Patients who continued on with the 1.0 mg dose also experienced a sustained reduction.
Nearly 10% of people living with HIV have to travel more than an hour to access HIV care, and those living in rural counties have drive times more than double that of those in urban counties.
The migration of care from inpatient to outpatient and ambulatory surgery center settings is revolutionizing healthcare delivery.
The National Comprehensive Cancer Network (NCCN) Thursday released its first set of clinical practice guidelines for pediatric cancer, saying the new acute lymphoblastic leukemia (ALL) guidelines are the first of several planned to address various pediatric cancers.
The World Health Organization (WHO) has included burnout in the International Classification of Diseases, 11th Revision (ICD-11); public health officials may refuse to renew the license of the last abortion provider in Missouri, which would make the state the only one in the country without access to a legal abortion provider; organizations have announced a research initiative to identify why immunotherapy causes diabetes in some patients with cancer.
Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes.
The median lag time from first-in-human to first-in-child trials of oncology drugs that were ultimately approved by FDA is 6.5 years.
If we had a consumer-centered, market-based model that required transparency in costs and quality, accountability across the continuum with payments tied to outcomes, and real competition based on data that is made available in consumer-friendly ways, we wouldn't have the problem with surprise bills we see today.
Amarin announced that its supplemental new drug application for Vascepa has been accepted for filing and granted Priority Review designation by the FDA; civil rights groups ask a federal court to strike down an HHS "conscience" rule that may limit services covered by providers and payers that violate religious or moral beliefs; US Representive Seth Moulton, D-Massachusetts, unveils a new military mental health proposal.
Here are 5 interesting findings from the May 2019 issue of AJMC®.
Chronic obstructive pulmonary disease (COPD) is associated with shorter survival and marked differences in early stages of non-small cell lung cancer (NSCLC).
Researchers in Australia studying thunderstorm-triggered asthma suggested that ways to better stratify at-risk individuals are needed.
FDA approved alpelisib (Piqray), an oral drug to be used in combination with endocrine therapy fulvestrant for the treatment of men and postmenopausal women with hormone receptor (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following disease progression on or after an endocrine-based regimen.
The FDA approved ruxolitinib (Jakafi) for another indication, this time for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.
A study has found that 28% of men and 26% of women between the ages of 35 and 50 years have osteopenia and are at risk for osteoporosis.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
